|
|
|
| Clinical observation of docetaxel combined with cisplatin in treatment of advanced non-small cell lung cancer |
| GUO Xiaoying1, SHEN Guohong2,SUN Changyon1, LI Ying3, GENG Li2 |
| 1.Department of Pharmacy, 2.Department of Oncology, 3.Department of Medicine,Shanxi Provincial Crops Hospital, Chinese People’s Armed Police Forces, Taiyuan 030006, China |
|
|
|
|
Abstract Objective To study the efficacy and toxicities of docetaxel combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer (NSCLC). Methods 214 patients with advanced NSCLC confirmed pathlogically and/or cytologically from May 2012 to May 2014 were divided into two groups, group one (n=79) received first-line chemotherapy, the other group (group two, n=135) received second-line chemotherapy. The two groups were given docetaxel 75 mg/m2, D1; plus cisplatin 80 mg/m2, D1-3. The process was repeated every 3 weeks. The efficacy and toxicities were assessed after 2 cycles. Results The total efficacy was 25.23%. The two groups had no CR patient. The effective rate in the two groups were 31.64% and 21.48% respectively (P=0.283). The major toxicity was myelosuppression, nausea and vomiting. The III/IV° myelosuppression was 10.75%. The serious reduction rates of platelets in the two groups were 2.53% and 8.15%, respectively(P＜0.05). There was no other obviously different side effects in the two groups. Conclusions The combined chemotherapy of docetaxel with cisplatin is effective in the treatment of advanced NSCLC patient,especially in liver metastasis, and toxicities are tolerable.
|
|
Received: 11 February 2015
|
|
|
|
|
|
| [1] |
支修益. 我国肺癌流行病学现状分析[J].中国处方药,2009,15(2):56-57.
|
| [2] |
胡炳强, 欧阳取长,陈艳平. 有关我国非小细胞肺癌诊治的一些思考[J].中国现代实用医学杂志,2008, 7(8): 25-28.
|
| [3] |
陈首英, 刘福林, 庞志刚,等. 肺癌病人5年生存率及生存因素分析[J].预防医学文献信息,2004, 10(l): 1-3.
|
| [4] |
范 江,姜格宁. 非小细胞肺癌治疗进展[J].中华临床医师杂志,2008, 2 (1): 11-14.
|
| [5] |
Raez L E, Lilenbaum R. New developments in chemotherapy for advanced non-small cell lung cancer [J]. Curr Opin Oncol, 2006, 18(2): 156-161.
|
| [6] |
Puglisi F, Barbone F, Tell G, et al. Prognostic role of Ape/Ref-1 subcellular expression in stage I-III breast carcinomas [J]. Oncol Rep, 2002, 9(1):11-18.
|
| [7] |
Schiller J H, Harrington D, Belani C P, et al. Comparison of four chemotherapy regiments for advanced non-small cell lung cancer [J]. N Engl Med, 2002, 346: 92-98.
|
| [8] |
孙 燕, 周际昌. 临床肿瘤内科手册[M] . 北京: 人民卫生出版社, 2003: 97-107.
|
| [9] |
刘太省,吴 华,庄贤勉.铂类联合多西他赛或长春瑞滨一线治疗晚期非小细胞肺癌的meta分析[J].中国肺癌杂志,2014,17(4): 327-335.
|
| [10] |
陈颖波, 陈 嘉, 陈凌翔. 多西他赛联合顺铂3周方案与每周方案治疗非小细胞肺癌 [J]. 中国癌症杂志, 2005, 15(2): 169-170.
|
|
|
|
2015, Vol. 26 
